The biggest problem with medical cannabis in Oz is the complicated procedure for patients to actually access it, which is exacerbated by so many doctors being unwilling to prescribe it, and which is why we have only a few hundred patients (400?) actually using MC in Oz compared with a reported 30,000 in Israel.
I believe that Australian companies operating in overseas markets for medicinal cannabis and nutraceuticals, and Oz companies exporting to countries where the products are legalised, will have an edge on the Oz companies which rely solely on the local MC market; but the Australian hemp companies have a huge advantage because they are already up and running in a rapidly growing market.
That's why I'm so firmly of the belief that the big money over the next few years, and maybe permanently, will be in hemp products, which puts EXL followed by QBL in the box seat for actually making a profit.
The 2018 Q4 Quarterlies will show a much clearer picture of which companies are actually making money.
- Forums
- ASX - By Stock
- Ann: 2017 AGM Presentation
The biggest problem with medical cannabis in Oz is the...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EXL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.4¢ |
Change
-0.002(33.3%) |
Mkt cap ! $6.605M |
Open | High | Low | Value | Volume |
0.4¢ | 0.5¢ | 0.4¢ | $2.103K | 475.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 7670493 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 924824 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 3797 | 4.490 |
1 | 8000 | 4.480 |
2 | 6000 | 4.470 |
1 | 358 | 4.460 |
3 | 3424 | 4.450 |
Price($) | Vol. | No. |
---|---|---|
4.500 | 31 | 1 |
4.510 | 342 | 1 |
4.520 | 397 | 1 |
4.530 | 370 | 1 |
4.540 | 825 | 2 |
Last trade - 14.04pm 29/11/2024 (20 minute delay) ? |
EXL (ASX) Chart |